Delivering synthetic and medicinal chemistry solutions to global pharma and biotech customers for creating, identifying, and supporting the discovery of preclinical candidates (PCC’s) with our leading discovery chemistry platform.
20 of global top 20 pharmaceutical companies
516 clients have FTE collaboration
27 clients with 50+ FTE team including:13 clients with 100+ FTE teams
458 clients with >5 years’ collaboration including:75 clients with >10 years’ collaboration
FFS collaboration covers 1,200+ customers from mg to kg scale synthesis
11,000+ Regular FFS Projects per year, > 95% on time delivery rate
1,200+ DPC (Discovery Process Chemistry) Projects per year
FFS is well recognized by customers with high Net Promotion Score (NPS) over 85
WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations.
As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) from preclinical to commercial.
Integrated CMC platform for both API and drug product
8 development and manufacturing sites worldwide with one quality and EHS standard approved by all major regulatory agencies
Supported 23 new drugs approved in the US, Europe, China and Japan from 2017-2020
Supported 1,113 preclinical & phase 1, 220 phase II, 48 phase III and 32 commercial projects in 2021H1
Industry leading teams: 2,549 process chemists & analytical scientists for API platform; 1,192 formulation scientists & analytical scientists for drug product platform